
A doctor who treated children dying from HIV-related infections in the 1990s now leads one of South Africa’s most influential teams ensuring medical breakthroughs reach patients. Saiqa Mullick, director of implementation science at Wits RHI, fills the critical gap between research and real-world healthcare—a step that often determines whether life-saving treatments succeed or fail.
Her career began in a Nairobi hospital where she witnessed patients dying from preventable infections like tuberculosis and pneumonia, diseases that thrive when HIV compromises the immune system. At the time, antiretroviral therapy did not exist. Decades later, she transitioned from pediatric care to public health, looking for a way to make a bigger impact.
Implementation science reshapes global health priorities
In 2014, Mullick established Wits RHI’s implementation science directorate with a single staff member. A decade later, she leads a team of 200—now smaller after U.S. funding reductions—but her influence has expanded significantly. The field itself has transformed from an overlooked consideration to a priority, with developers now seeking ways to deploy products before finalizing them. “For a long time implementation science was an afterthought, but in recent years it has become a priority.
Developers have gone from asking ‘We’ve got a product, now how do we roll it out?’ to ‘We might have a product, how would we roll it out?’ It’s a fundamental shift that has happened because we’ve seen how mistakes in how a product is introduced can be really costly,” said Helen Rees, Wits RHI’s founder.
One of Mullick’s current projects, Len4PrEP, examines how to distribute lenacapavir (LEN), a six-month HIV injection that nearly eliminates transmission risk. Unlike daily oral PrEP, which South Africa has provided since 2016, LEN requires no daily adherence, only a clinic visit every six months. Mullick takes the lead in communicating new findings as they come in, like the fact that 86% of clients prefer the LEN injection over the daily pill.
A high number of men are asking for LEN, which has not been the case with oral PrEP, and many of the clients are what Mullick calls “PrEP naïve”, meaning they’ve never had PrEP before, and have come in specifically to ask for LEN. Other findings appear nondescript, like the fact that men are generally preferring the arm as the injection site with most women preferring the buttock, but insights like these can make an enormous difference. “It’s about choice,” she says,“People want choice in PrEP. They want choice in service delivery, with some preferring mobile clinics and others normal primary healthcare clinics. And they want to be able to choose where they get injected,” she says.
Lessons from history drive urgent action
The emphasis on implementation science reflects a broader lesson from history. The Royal Navy ignored evidence that citrus prevented scurvy for over 170 years, costing countless lives. South Africa cannot afford similar delays. With the world’s largest HIV epidemic and overlapping health crises, Mullick’s work ensures science translates into action rather than gathering dust.
Related Post: Floods Linked to Mental Health Issues in Africa
Her own journey mirrors the discipline she advocates. Born in Nairobi to parents who demanded rigorous discipline, her mother waking her at 4:30 a.m. for study sessions, Mullick initially pursued medicine to follow family tradition. Two of my uncles were doctors, and some of the other aunts and uncles were married to doctors, and so my plan was always to follow in their footsteps and go to medical school. After treating dozens of children in paediatrics, she switched to public health, looking for a way to make a bigger impact.
By 2002, she led global reproductive health programs for the Population Council, traveling across Africa. That gap became her lifelong mission.
Today, her team spans service delivery, community engagement, budgeting, and market strategies to reduce costs for underserved populations. The work demands diplomacy, adaptability, and trust in others’ expertise. Colleagues praise her ability to listen, adjust when necessary, and empower teams without micromanaging.
PrEP injections reveal hidden clinic challenges
The Len4PrEP study has uncovered unexpected patterns in HIV prevention engagement. While the six-month lenacapavir injection aligns with South Africa’s existing PrEP infrastructure, government clinics already stock daily oral PrEP, its adoption has exposed service delivery gaps. Some clinics lack proper refrigeration for the injectable, forcing temporary storage in freezers or borrowed coolers. Others face staff shortages, particularly nurses trained to administer injections, creating bottlenecks during peak demand.
Mullick’s team documents these issues in real time, adjusting protocols as they arise. When data showed men overwhelmingly preferred arm injections while women favored the buttock, clinic staff received targeted training. The study also revealed access disparities: urban clinics, better resourced, reported higher LEN uptake than rural sites, where transportation remains a barrier. To address this, the team is testing mobile injection units in underserved areas, though logistical hurdles, such as securing fuel subsidies, have delayed expansion.
Funding cuts force leaner, smarter interventions
Mullick’s work extends beyond HIV, though the epidemic remains central. Challenges remain. Funding instability has forced her team to shrink from 600 to 200 members, requiring a focus on high-impact, low-cost interventions. Mullick now prioritizes training community health workers to manage minor PrEP or LEN side effects, freeing clinic staff for complex cases.